JPMorgan analyst Casey Woodring downgraded Syneos Health to Underweight from Neutral with a price target of $28, down from $30. The firm says it has little visibility into improvement in the company’s clinical business in 2023 "against a heightened competitive backdrop." The relative risk/reward of shares is skewed negatively given the uncertainty around 2023 estimates and the longer-term competitive positioning of Syneos Health’s clinical business, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Schedules Fourth Quarter and Full Year 2022 Earnings Call for Thursday, February 16th, 2023
- Syneos Health partners with Equicare, to accelerate clinical trial research
- Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research
- Syneos Health and Haystack Health Partner to Accelerate Clinical Trials with AI
- Syneos Health, Haystack Health partner to accelerate trials with AI
